Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared Uromigos‘s post on X, adding:
“Disitamab Vedotin plus toripalimab was developed exclusively in China.
Here Dr Yige Bao describes 4 other ADCs in phase III, also in China. Some of these are likely to be globally impactful. The video peers into the future of UC.
It’s worth a look.”
Quoting Uromigos’s post:
“After the success of Disitamab Vedotin plus toripalimab in bladder cancer at ESMO25, we asked what other randomised trial are ongoing in China ?
In this Uromigos Short Dr Yige Bao describes a number of new RIII studies.”
Proceed to the video attached to the post.
More posts featuring Tom Powles.